Pune, Oct. 17, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the skin cancer treatment market should point to $17.49 billion by 2030 and grow to a 7.4% CAGR during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled “Skin Cancer Treatment Market – Global Outlook & Forecast 2022-2030”
Download PDF Brochure of Skin Cancer Treatment Market Size – Impact of COVID-19 and Global Analysis with Strategic Developments on: https://growthplusreports.com/inquiry/request-sample/skin-cancer-treatment-market/7877
The prevalence of skin cancer in the population is relatively high among other cancers. Skin cancers, including melanoma, squamous cell cancer, basal cell carcinoma, and others, are caused by the abnormal development of skin cells. For the treatment of skin cancer, various therapies are used including chemotherapy, radiation therapy, phototherapy, etc. The global skin cancer treatment market is primarily driven by the growing population of skin cancer patients and improving approval rates of innovative therapies.
The global skin cancer treatment market has witnessed promising growth in recent years. This progress can be attributed to the increasing prevalence of skin cancer, increased awareness, increasing approval rates for new treatments, and growing government initiatives for early detection and treatment. Furthermore, a strong product portfolio will also pave the way for new growth opportunities in the market. Conversely, the major market constraints are the side effects of chemotherapy and radiotherapy and the resulting preference for surgical procedures.
The skin cancer treatment market has been analyzed from four angles: type, therapy, end users and region.
Excerpts from ‘By segmentation by type of therapy’
Based on therapies, the global skin cancer treatment market has been segmented in:
- Targeted therapy
- Others (photodynamic therapy, biological therapy, cryotherapy, etc.)
Currently, chemotherapy leads the global skin cancer treatment market in terms of revenue share. Chemotherapy is a main method used to treat skin cancer because this method not only kills the targeted cancer cells and eliminates or reduces the risk of cancer cells spreading (metastasis). These factors contribute to the greater use of chemotherapy for the treatment of skin cancer. However, high side effects and the resulting preference for surgical procedures challenge the growth of the chemotherapy and radiation therapy segments.
The immunotherapy segment is expected to grow rapidly over the forecast period. Immunotherapy focuses on stimulating the patient’s immune system, thereby destroying cancer cells with the help of the immune system. Also, immunotherapy has minimal side effects on patients, making it a more suitable option for the treatment of skin cancer, thus indicating the rapid adoption of immunotherapy.
Inquiry before buying: https://growthplusreports.com/inquiry/before-buying/skin-cancer-treatment-market/7877
Excerpts from ‘Segmentation by region’
The global skin cancer treatment market has been segmented into:
- North America
- Asia Pacific
- Rest of the world
North America leads the global market with the largest revenue share owing to the high prevalence of skin cancer and increasing drug and treatment approvals. Additionally, increased technological innovations and the presence of multiple market players are enhancing the dominance of the North American market.
On the other hand, the Asia-Pacific skin cancer treatment market is expected to grow rapidly. This growth can be attributed to the increase in government initiatives for early diagnosis and treatment of skin cancer and the high adoption of generic drugs. In addition, the rapid development of healthcare infrastructure and growing medical tourism in the Asia-Pacific region are contributing to the development of the market.
Excerpts from “Competitive Landscape”
Prominent Players Operating in the Skin Cancer Treatment Market are
- Regeneron Pharmaceuticals, Inc.
- Amgen Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- CRS Holdings LLC
- Sun Pharmaceutical Industries Ltd
- Merck & Co.
- F. Hoffmann-La Roche SA
- Novartis AG
- GlaxoSmithKline plc
- Market ecosystem
- Schedule under study
- Historical years – 2020
- Base year – 2021
- Planned years – 2022 to 2030
- Currency used in the report
- RESEARCH METHODOLOGY
- Research approach
- Data collection methodology
- Information source
- Secondary sources
- Primary sources
- Market estimation approach
- From bottom to top
- From top to bottom
- Market Forecast Model
- Limits and assumptions
- PREMIUM OVERVIEW
- Current market trends (COVID-19 outlook)
- Key players and competitive positioning (2021)
- MARKET DYNAMICS
- GLOBAL SKIN CANCER TREATMENT MARKET – ANALYSIS AND FORECAST, BY TYPES
- Basal cell carcinoma
- Squamous cell cancer
- Others (lymphoma, Kaposi’s sarcoma, etc.)
- GLOBAL SKIN CANCER THERAPY MARKET – ANALYSIS AND FORECAST, BY TYPE OF THERAPY
- Targeted therapy
- Others (Photodynamic Therapy, Biological Therapy, Cryotherapy, etc.)
- GLOBAL SKIN CANCER THERAPY MARKET – ANALYSIS AND FORECAST, BY END USER
- Cancer research centers
- Specialized clinics
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Fueled by free analyst hours and expert interviews with every report
- Comprehensive quantitative and qualitative information at segment and sub-segment level
- Trends and perspectives of the impact of Covid 19
- Granular information at global/regional/country level
- In-depth insights into market dynamics (drivers, restraints, opportunities) and business environment
- Global coverage of the competitive landscape
- Winning imperatives
- Comprehensive coverage of “strategic developments” recorded by major market players
- Distributor Landscape Assessment
- Pricing information
- Customer evaluation
- Analysis of investments and initiatives
- ‘Company Profile’ of key players
Buy Directly Premium Copy of Skin Cancer Treatment Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=1xvTpwPdN4k0eDDemJtzdypSLCjYHV0Z8v9MmvQa&report_id=7877&license=Single
Growth Plus Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).
The Growth Plus portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable solutions and breakthroughs that set them up for future growth and success.
We have been recognized by the prestigious CEO Magazine as “The Most Innovative Market Research Company in the Healthcare Market of 2020.